Alagille 综合征治疗市场
Alagille 综合征治疗市场：2026年市场规模约为9.5亿美元，2031年市场规模约为14.1亿美元；预测期复合年增长率为8.22%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
待补内容：缺少制约因素核心结论
Alagille 综合征治疗市场：2026年市场规模约为9.5亿美元，2031年市场规模约为14.1亿美元；预测期复合年增长率为8.22%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 8.22% | 机构预测 |
| 市场规模 | 2026 | USD 0.95 billion | 机构预测 |
| 市场规模 | 2031 | USD 1.41 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| drug_class_and_active_ingredient | ileal bile acid transporter inhibitors | 2025 | 38.550% |
| end_user | pediatric hepatology centers | 2025 | 42.670% |
| geography | North America | 2025 | 38.670% |
| patient_age_group | children aged 1 to 11 years | 2025 | 65.000% |
| route_of_administration | oral formulations | 2025 | 81.450% |
| treatment_modality | pharmacological therapy | 2025 | 61.240% |
关键结论
- drug_class_and_active_ingredient 维度中，ileal bile acid transporter inhibitors 在 2025 年的公开份额为 38.55%。
- end_user 维度中，pediatric hepatology centers 在 2025 年的公开份额为 42.67%。
- geography 维度中，North America 在 2025 年的公开份额为 38.67%。
- patient_age_group 维度中，children aged 1 to 11 years 在 2025 年的公开份额为 65%。
- route_of_administration 维度中，oral formulations 在 2025 年的公开份额为 81.45%。
- treatment_modality 维度中，pharmacological therapy 在 2025 年的公开份额为 61.24%。
主要参与者
- Mirum Pharmaceuticals, Inc.
- Ipsen Pharma
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Company Limited
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Expansion of approved IBAT inhibitor use across pediatric age groups | +2.100% | Global, led by North America and Europe | Short term (≤ 2 years) |
| Regulatory recognition of cholestatic pruritus as a treatable endpoint | +1.400% | Global, with early gains in North America, EU, and Japan | Short term (≤ 2 years) |
| Increasing genetic diagnosis of JAG1 and notch2-associated disease | +1.000% | Global, accelerating in Asia-Pacific and South America | Medium term (2-4 years) |
| Expansion of specialized pediatric liver-care networks | +0.800% | Asia-Pacific core, with spillover to Middle East and Africa | Medium term (2-4 years) |
| Drug-formulation requirements created by rapid weight and feeding changes in infants | +0.500% | Global | Medium term (2-4 years) |
| Patient-reported itch and sleep outcomes becoming reimbursement evidence | +0.600% | North America and EU, with early signals in Japan and Canada | Short term (≤ 2 years) |
报告关注的关键问题
What is the projected value of Alagille syndrome treatment by 2031?
The Alagille syndrome treatment market is estimated to reach USD 1.41 billion by 2031, from USD 0.95 billion in 2026, at a CAGR of 6.50%.
Which treatment modality had the largest share in 2025?
Pharmacological therapy held the largest share at 61.24% in 2025, supported by targeted IBAT inhibitors and supportive medicines.
Which medicine is expected to grow fastest through 2031?
Maralixibat is the fastest-growing active ingredient, with a forecast CAGR of 10.80% from 2026 to 2031.
Why are genetic clinics becoming more important for Alagille syndrome care?
Greater use of JAG1 and NOTCH2 testing can improve diagnostic confirmation and channel patients into specialist care. Specialty genetic clinics are forecast to grow at a 10.55% CAGR.
Which region is forecast to grow fastest through 2031?
Asia-Pacific is forecast to grow at a 9.58% CAGR, supported by developments in Japan, China, and Australia. The Alagille syndrome treatment market is expected to gain from these developments.
What factors can limit treatment uptake?
Small diagnosed patient numbers, high treatment costs, reimbursement delays, and adverse effects such as diarrhea, abdominal pain, and vitamin deficiency can limit access and continued use.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence